These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 23834452

  • 1. Population pharmacokinetic analysis of axitinib in healthy volunteers.
    Garrett M, Poland B, Brennan M, Hee B, Pithavala YK, Amantea MA.
    Br J Clin Pharmacol; 2014 Mar; 77(3):480-92. PubMed ID: 23834452
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
    Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP.
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
    [Abstract] [Full Text] [Related]

  • 4. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.
    Pithavala YK, Tong W, Mount J, Rahavendran SV, Garrett M, Hee B, Selaru P, Sarapa N, Klamerus KJ.
    Invest New Drugs; 2012 Feb; 30(1):273-81. PubMed ID: 20740300
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
    Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ.
    J Clin Pharmacol; 2013 May; 53(5):491-504. PubMed ID: 23553560
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.
    Chen Y, Rini BI, Bair AH, Mugundu GM, Pithavala YK.
    Clin Pharmacokinet; 2015 Apr; 54(4):397-407. PubMed ID: 25343945
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
    Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
    Igarashi R, Inoue T, Fujiyama N, Tsuchiya N, Numakura K, Kagaya H, Saito M, Narita S, Satoh S, Niioka T, Miura M, Habuchi T.
    Med Oncol; 2018 Mar 09; 35(4):51. PubMed ID: 29524031
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
    Smith BJ, Pithavala Y, Bu HZ, Kang P, Hee B, Deese AJ, Pool WF, Klamerus KJ, Wu EY, Dalvie DK.
    Drug Metab Dispos; 2014 May 09; 42(5):918-31. PubMed ID: 24608633
    [Abstract] [Full Text] [Related]

  • 19. Effect of axitinib on the QT interval in healthy volunteers.
    Ruiz-Garcia A, Houk BE, Pithavala YK, Toh M, Sarapa N, Tortorici MA.
    Cancer Chemother Pharmacol; 2015 Mar 09; 75(3):619-28. PubMed ID: 25589220
    [Abstract] [Full Text] [Related]

  • 20. Concise drug review: pazopanib and axitinib.
    van Geel RM, Beijnen JH, Schellens JH.
    Oncologist; 2012 Mar 09; 17(8):1081-9. PubMed ID: 22733795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.